SBIR Phase I: Development of a Novel Biosensor to Accelerate Investigations of COVID-19 and the Gut Microbiome.

SBIR 第一阶段：开发新型生物传感器以加速 COVID-19 和肠道微生物组的研究。

• 批准号: 2035981
• 负责人: Dylan Nichols
• 金额: $ 25.57万
• 依托单位: BIOMESENSE, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-01-15 至 2021-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2035981&HistoricalAwards=false
• 关键词: SBIR; Phase; Development; Novel; Biosensor

The broader impact of this Small Business Innovation Research (SBIR) Phase I project will be advanced understanding of the interaction between SARS-CoV-2, COVID-19, and the human gut microbiome, potentially resulting in new treatment approaches for COVID-19 patients. This project will develop a novel biosensor to enable low-cost, highly standardized studies of links between the human gut microbiome and COVID-19 to help evaluate the performance of different therapeutic approaches, drugs, vaccines, and other clinical interventions. Finally, once this project is successfully completed, there is a longer-term opportunity to add detection capability to the technology, enabling real-time, at-home tracking of SARS-CoV-2 prevalence in stool samples of high-risk patients and their caretakers. This would enable the technology to become a continuous viral detection tool.The proposed project will advance a sensor to allow isolation and preservation of microbial RNA from stool samples. Existing technique preserve microbial DNA but are not sensitive enough to preserve the far less stable RNA. The project will evaluate candidate extraction and fixative reagents based on technical performance, length of RNA stability, reagent cost, and storage requirements. Simultaneously, the project will develop an advanced systems architecture enabling a scalable solution for widespread use.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该小企业创新研究 (SBIR) 第一阶段项目的更广泛影响将是加深对 SARS-CoV-2、COVID-19 和人类肠道微生物组之间相互作用的了解，从而可能为 COVID-19 患者带来新的治疗方法。 该项目将开发一种新型生物传感器，以实现对人类肠道微生物组与 COVID-19 之间联系的低成本、高度标准化的研究，以帮助评估不同治疗方法、药物、疫苗和其他临床干预措施的性能。最后，一旦该项目成功完成，就有了一个更长期的机会为该技术增加检测能力，从而能够实时、在家跟踪高危患者及其粪便样本中 SARS-CoV-2 的流行情况。看护者。这将使该技术成为一种连续的病毒检测工具。拟议的项目将改进一种传感器，以从粪便样本中分离和保存微生物 RNA。 现有技术可以保存微生物 DNA，但不够灵敏，无法保存稳定性差得多的 RNA。该项目将根据技术性能、RNA 稳定性长度、试剂成本和存储要求来评估候选提取和固定试剂。同时，该项目将开发一种先进的系统架构，实现可扩展的解决方案以供广泛使用。该奖项反映了 NSF 的法定使命，并通过使用基金会的智力优点和更广泛的影响审查标准进行评估，被认为值得支持。